Company Valerio Therapeutics London S.E.

Valerio Therapeutics is a clinical-stage biotechnology company developing novel cancer drugs by targeting tumor DNA functions through unparalleled mechanisms of action in the highly sought-after field of DNA damage response (DDR). The company focuses on the development of innovative first-in-class or disruptive compounds (in-house, acquired or licensed) from translational research to human clinical proof of concept. Valerio Therapeutics has platON®, its proprietary decoy oligonucleotide chemistry platform, and V-Body, the platform for generating single-domain therapeutic antibodies. These two proprietary platforms are dedicated to the generation of innovative new compounds to enrich the company's product portfolio.

AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company, and V-Body, the platform for generating single-domain therapeutic antibodies. These two proprietary platforms are dedicated. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing VIO-01 (previously OX425), a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. The clinical development of VIO-01 was stopped in early 2025 in order to redirect research and development efforts towards next-generation drug candidates based on the PlatON and VBody platforms.

Number of employees: 25